AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Objectives
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention
of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin
increases with the severity of atrial cardiopathy.
Phase:
Phase 3
Details
Lead Sponsor:
Columbia University
Collaborators:
Bristol-Myers Squibb Medical University of South Carolina National Institute of Neurological Disorders and Stroke (NINDS) Pfizer Roche Pharma AG University of Cincinnati University of Washington Weill Medical College of Cornell University